STAT+: With new strategy, Novo outlines plans for obesity, direct-to-consumer work
Under investor pressure, Novo presented its strategy to both grow its obesity franchise and diversify its pipeline.
Novo Nordisk, in an effort to regain investor confidence, unveiled its strategy for future growth on Monday, focusing on diversification and expansion of its product pipeline. The company aims to launch at least five multi-blockbuster drugs by 2030, with the goal of generating revenue growth comparable to other major pharmaceutical firms.
CEO Mike Doustdar announced a shift towards investing more in disease areas beyond diabetes and obesity, indicating a move towards treating these conditions more like consumer goods than conventional medications.
During the company's capital markets day, held in London, Doustdar acknowledged investor concerns regarding Novo's heavy reliance on its GLP-1 drugs and the need to develop other products. This strategy reflects a broader effort to reduce dependency on a single product line while investing in new areas of research and business development.
The announcement drew a 5% drop in Novo Nordisk's share price during CEO Doustdar's opening remarks, highlighting that investors were seeking more concrete details about the company's future plans.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
